Ongentys (opicapone) is a small molecule pharmaceutical. Opicapone was first approved as Ongentys on 2016-06-24. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against catechol O-methyltransferase. Ongentys's patents are valid until 2035-05-27 (FDA).
|Drug Class||Catechol-O-methyltransferase (COMT) inhibitors|